Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
  • Users Online: 2268
  • Home
  • Print this page
  • Email this page

   Table of Contents      
LETTER TO THE EDITOR
Year : 2009  |  Volume : 57  |  Issue : 3  |  Page : 243-244

Comparison of single injection of intravitreal triamcinolone versus single injection of intravitreal bevacizumab in macular edema secondary to branch retinal vein occlusions with regard to changes in best corrected visual acuity and central macular thickness in the short term


National Institute of Ophthalmology, Pune, India

Date of Web Publication20-Apr-2009

Correspondence Address:
Aditya S Kelkar
1187/30 off Ghole Road, Shivajinagar, National Institute of Ophthalmology, Pune - 411 005, Maharashtra
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0301-4738.49408

Rights and Permissions

How to cite this article:
Kelkar AS, Sayyad MG, Kelkar JA, Kelkar SB, Narvankar R, Shaikh A. Comparison of single injection of intravitreal triamcinolone versus single injection of intravitreal bevacizumab in macular edema secondary to branch retinal vein occlusions with regard to changes in best corrected visual acuity and central macular thickness in the short term. Indian J Ophthalmol 2009;57:243-4

How to cite this URL:
Kelkar AS, Sayyad MG, Kelkar JA, Kelkar SB, Narvankar R, Shaikh A. Comparison of single injection of intravitreal triamcinolone versus single injection of intravitreal bevacizumab in macular edema secondary to branch retinal vein occlusions with regard to changes in best corrected visual acuity and central macular thickness in the short term. Indian J Ophthalmol [serial online] 2009 [cited 2020 Jul 11];57:243-4. Available from: http://www.ijo.in/text.asp?2009/57/3/243/49408

Dear Editor,

We would like to present our experience of single injection of intravitreal triamcinolone (IVTA) versus single injection of intravitreal bevacizumab (IVB) in macular edema secondary to branch retinal vascular occlusions with regard to changes in best corrected visual acuity and central macular thickness in the short term.

Our retrospective study consisted of 18 patients (mean age 55.3 yers, 62% males) who received IVTA (0.1ml containing 4mg) or IVB (0.05ml containing 1.25mg) during the period October 2007 to February 2008. All the patients included had non-ischemic branch retinal vein occlusion with macular edema which was confirmed on fluorescein angiography. The patients having best corrected visual acuity (BCVA) of 20/40 or poor with persistent macular edema for at least three months were included. (median duration for IVTA 3.8 months; IVB 3.6 months and mean duration IVTA group: 3.5 months;; IVB group 3.1 months).

Visual acuity, intraocular pressure (IOP), anterior segment, posterior segment findings and macular thickness (performed on three-dimensional optical coherence tomography) were noted (pre-injection, post-injection Day 1, 7, 30, 90). Of 18 patients, eight received IVTA and the rest were given IVB. The BCVA was similar in both groups at first post-injection day (IVTA P = 0.470; IVB P = 0.100) i.e. majority of patients (six out of eight in the IVTA group and eight out of 10 in the IVB group) had stable visual acuity (no improvement) on first post-injection day. However, at seventh post-injection day (IVTA P = 0.024; IVB P = 0.640), one month (IVTA P = 0.043; IVB P = 0.244) and three months (IVTA P = 0.047; IVB P = 0.290) the BCVA was significantly better in the IVTA group. The percent reduction in central macular thickness was significant at one week, one month and three months (one week: IVTA 32.3% vs. Bevacizumab 24.9% [ P = 0.029], one month: 36.2% vs. 21.4%[ P = 0.014], three months: 39.8% vs. 25.4% [ P = 0.014]). However, at first day post injection there was no significant difference in reduction of central macular thickness (20.36% vs. 20.45% P = 0.922).

At all follow-ups except first post-injection day, IOP was significantly higher in the IVTA group (one week: P = 0.021, one month: P = 0.034, three months: P = 0.029).

In a study by Pacolla et al ., [1] of 26 patients (26 eyes) with diabetic macular edema, the central macular thickness was significantly reduced in the IVTA group compared with the bevacizumab group at weeks 4, 8, 12 and 24 ( P < 0.05).

BCVA was significantly higher at eight and 12 weeks in the IVTA group compared with the bevacizumab group ( P < 0.05). On similar lines, our short-term results indicate that IVTA has better efficacy over bevacizumab in the management of macular edema secondary to branch retinal vein occlusions, specifically with regard to changes in BCVA and central macular thickness . However, the elevated IOP after IVTA is common [2] and since the prevalence of glaucoma/ocular hypertension is significantly higher in patients with central retinal vein occlusion and hemicentral retinal vein occlusion, [3] the IOP should be closely monitored in patients receiving IVTA.

 
  References Top

1.
Paccola L, Costa RA, Folgosa MS, Barbosa JC, Scott IU, Jorge R. Intravitreal triamcinolone versus bevacizumab for treatment of refractory diabetic macular oedema (IBEME study). Br J Ophthalmol 2008;92:76-80.  Back to cited text no. 1
[PUBMED]  [FULLTEXT]  
2.
Rhee DJ, Peck RE, Belmont J, Martidis A, Liu M, Chang J, et al . Intraocular pressure alterations following intravitreal triamcinolone acetonide. Br J Ophthalmol 2006;90:999-1003.  Back to cited text no. 2
[PUBMED]  [FULLTEXT]  
3.
Hayreh SS, Zimmerman MB, Beri M, Podhajsky P. Intraocular pressure abnormalities associated with central and hemicentral retinal vein occlusion. Ophthalmology 2004;111:133-41.  Back to cited text no. 3
[PUBMED]  [FULLTEXT]  



This article has been cited by
1 Branch Retinal Vein Occlusion: Treatment Modalities: An Update of the Literature
Irini P. Chatziralli,Adil Jaulim,Vasileios G. Peponis,Panagiotis G. Mitropoulos,Marilita M. Moschos
Seminars in Ophthalmology. 2013; : 1
[Pubmed] | [DOI]
2 Changes in aqueous cytokines after intravitreal triamcinolone versus bevacizumab for macular oedema in branch retinal vein occlusion
Hee Jin Sohn,Dae Heon Han,Dae Yeong Lee,Dong Heun Nam
Acta Ophthalmologica. 2013; : n/a
[Pubmed] | [DOI]
3 Behandlung der Patienten mit einem Venenastverschluss in Abhängigkeit von der Verschlussdauer
M. Rehak,E. Spies,M. Scholz,P. Wiedemann
Der Ophthalmologe. 2013; 110(10): 966
[Pubmed] | [DOI]



 

Top
 
 
  Search
 
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

 
  In this article
References

 Article Access Statistics
    Viewed2023    
    Printed40    
    Emailed1    
    PDF Downloaded391    
    Comments [Add]    
    Cited by others 3    

Recommend this journal